Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis

Anil R Maharaj1, Huali Wu1, Kanecia O Zimmerman1,2

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Insights

This study developed a population pharmacokinetic model for fentanyl in obese children, finding a model-based infusion strategy improves target concentration achievement. This research is crucial for optimizing pediatric pain management.

Area of Science:

  • Pharmacology
  • Pediatric Anesthesiology
  • Pharmacometrics

Background:

  • Fentanyl pharmacokinetics (PK) differences between obese and nonobese adults are known, but data on childhood obesity's impact is limited.
  • Understanding fentanyl PK in obese children is critical for safe and effective pain management.

Purpose of the Study:

  • To develop a population pharmacokinetic (PopPK) model for fentanyl in a cohort of predominantly obese children.
  • To evaluate continuous infusion strategies for achieving target steady-state fentanyl concentrations (Css) within an analgesic range (1-3 ng/mL).

Main Methods:

  • A PopPK model was developed using 53 samples from 32 children (94% obese).
  • A 2-compartment model, allometrically scaled by total body weight, was used.
  • A probability-based approach assessed different infusion strategies.

Main Results:

  • The model indicated typical fentanyl clearance of 32.5 L/h (scaled to 70 kg).
  • A fixed dose infusion (1 µg/kg/h) showed variable success in reaching target Css, with increased risk of exceeding 3 ng/mL in heavier children.
  • A proposed model-based strategy improved consistent achievement of target Css across varying body weights.

Conclusions:

  • Allometric scaling of clearance by weight is appropriate for intravenous fentanyl PK in obese children.
  • The developed model-derived infusion strategy optimizes fentanyl dosing to maximize the probability of achieving therapeutic concentrations in pediatric patients of diverse weights.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
173
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
215
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
202
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
214
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
136
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
200